Parallax Volatility Advisers
DMII

Parallax Volatility Advisers’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Parallax Volatility Advisers’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
+133,647
New +$1.33M ﹤0.01% 870

Other funds holding DMII

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Parallax Volatility Advisers's DMII Position: Q1 2026 in Review

Parallax Volatility Advisers opened a new position in Drugs Made In America Acquisition II Corp (DMII) in Q1 2026: 133,647 shares worth $1.34M. The stake represents ﹤0.01% of the portfolio and ranks #870 among its holdings.

68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • Parallax Volatility Advisers held 133,647 shares of Drugs Made In America Acquisition II Corp worth $1.34M as of Q1 2026.
  • Drugs Made In America Acquisition II Corp was a new Parallax Volatility Advisers position in Q1 2026.
  • Drugs Made In America Acquisition II Corp made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q1 2026, its #870 holding.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.